ImmunoFree, Inc, a US-based company that was founded in 2023 to improve the lives of transplant patients by using new stem cell technology to eliminate the need for immunosuppressive medications without fear of organ rejection, announced on Tuesday that it has named Dr Ephraim Fuchs as its new chief medical officer.

In the new role, Dr Fuchs will manage all of the company's medical and scientific matters and be responsible for the development of the ImmunoFree tolerance protocol for the 1,000,000 plus transplant recipients globally who can benefit from the elimination of immunosuppressive medications.

Dr Fuchs co-founded ImmunoFree and serves as the professor of Oncology & Immunology at the Johns Hopkins University School of Medicine.